Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Synopsys Signs $1 Billion Accelerated Share Repurchase Agreement

Synopsys Signs $1 Billion Accelerated Share Repurchase Agreement

MT newswireMT newswire2026/10/05 13:32

09:32 AM EDT, 10/05/2026 (MT Newswires) -- Synopsys (SNPS) said Monday it has entered into an accelerated share repurchase agreement with JPMorgan Chase (JPM) subsidiary JPMorgan Chase Bank, National Association, to repurchase $1 billion of Synopsys stock. Under the terms of the agreement, Synopsys will receive an initial share delivery of around 1.7 million shares, with any remainder to be settled on or before Jan. 5, 2027, upon completion of the repurchases, according to a statement.

09:32 AM EDT, 10/05/2026 (MT Newswires) -- Synopsys (SNPS) said Monday it has entered into an accelerated share repurchase agreement with JPMorgan Chase (JPM) subsidiary JPMorgan Chase Bank, National Association, to repurchase $1 billion of Synopsys stock. Under the terms of the agreement, Synopsys will receive an initial share delivery of around 1.7 million shares, with any remainder to be settled on or before Jan. 5, 2027, upon completion of the repurchases, according to a statement.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Amgen (AMGN.US) and AstraZeneca (AZN.US) combination therapy extends small cell lung cancer survival by eight months, reduces risk of death by 58%

Researchers combined Amgen's Imdelltra with AstraZeneca's Imfinzi and found that for patients with aggressive lung cancer whose tumors had already spread, this combination extended survival by about eight months compared to Imfinzi monotherapy. Small cell lung cancer is one of the cancer types with the worst prognosis.

智通财经•2026/10/25 02:56
Amgen (AMGN.US) and AstraZeneca (AZN.US) combination therapy extends small cell lung cancer survival by eight months, reduces risk of death by 58%